Individual Tumor Profiling
Has Tumor Molecular Profiling Enabled More Effective and Less Toxic Cancer Treatment?
Top 10 Under 40
Up-and-Coming Stars Shine in Biopharma Research and Business
Podcast: FDA’s New Commissioner Hits the Ground Running
Scott Gottlieb, M.D., Commits to Speeding Up Drug Reviews, and Maintaining Safety and Efficacy
Liquid Biopsies Remain Wait and See for Some Clinicians
Circulating Biomarker Assays Promise to Refresh Cancer Profiling and Monitoring Practices
For full access to this article login to GEN Select now.
Inflammation Research Leads to Targets
Safer and More Effective Drugs Are the Focus
- Late last month, GlaxoSmithKline (GSK; www.gsk.com) and ChemoCentryx (www.chemocentryx.com) signed a multitarget strategic alliance, potentially worth 1.5 billion, to discover, develop, and market novel medicines targeting four chemokine and chemoattractant receptors for the treatment of a variety of inflammatory disorders. ChemoCentryx will be responsible for the discovery and ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.